Alicja Przybylska

Mrs. Alicja Przybylska

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KDKatarzyna Dopierała
Katarzyna Dopierała
APAlicja Przybylska
Alicja Przybylska
KKKarolina Kustrzyńska
Karolina Kustrzyńska
BMBozena Michniak-Kohn
Bozena Michniak-Kohn

Verified
Journal Article
Open access
PDF file
APAlicja Przybylska
Alicja Przybylska
INIrina Naletova
Irina Naletova
Francesco AttanasioFrancesco Attanasio
Francesco Attanasio
KDKatarzyna Dopierała
Katarzyna Dopierała
Agnieszka Kołodziejczak-RadzimskaAgnieszka Kołodziejczak-Radzimska
Agnieszka Kołodziejczak-Radzimska
Cristina SatrianoCristina Satriano
Cristina Satriano
Graphene oxide (GO)–lipid hybrid nanostructures represent a promising class of multifunctional platforms for drug delivery and fluorescence-guided cellular imaging. In this study, we developed a graphene oxide-supported lipid bilayer system composed of rhodamine-labeled phosphatidylcholine (POPC-Rhod) for the delivery of the repurposed antispasmodic drug alverine citrate (ALV) to neuroblastoma cells. The hybrid nanostructures were assembled using two drug-loading strategies and characterized by UV–Vis spectroscopy, fluorescence analysis, dynamic light scattering, and atomic force microscopy to evaluate molecular interactions, vesicle size distribution, and nanomechanical properties. In vitro studies were performed using human neuroblastoma SH-SY5Y cells and their retinoic acid-differentiated neuronal-like counterparts. Confocal microscopy confirmed efficient cellular uptake of the fluorescent lipid–graphene hybrids, while viability and mitochondrial reactive oxygen species assays revealed differentiation-dependent cellular responses. ALV-loaded hybrids induced cytotoxic effects in proliferating neuroblastoma cells, whereas differentiated neuron-like cells exhibited greater tolerance and, at moderate concentrations, preserved viability despite increased oxidative stress. These findings demonstrate that graphene oxide–lipid hybrids can act as fluorescence-traceable drug delivery platforms and highlight the potential of alverine as a candidate for repurposing in neural cancer models. The system presented here provides a proof-of-concept framework for the development of multifunctional nanocarriers integrating therapeutic delivery with imaging capabilities.